301 related articles for article (PubMed ID: 32215167)
1. Intraplatelet L-Arginine-Nitric Oxide Metabolic Pathway: From Discovery to Clinical Implications in Prevention and Treatment of Cardiovascular Disorders.
Gawrys J; Gajecki D; Szahidewicz-Krupska E; Doroszko A
Oxid Med Cell Longev; 2020; 2020():1015908. PubMed ID: 32215167
[TBL] [Abstract][Full Text] [Related]
2. The DDAH-ADMA-NOS pathway.
Leiper JM
Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
[TBL] [Abstract][Full Text] [Related]
3. The biology and therapeutic potential of the DDAH/ADMA pathway.
Arrigoni F; Ahmetaj B; Leiper J
Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.
Dimitroulas T; Sandoo A; Kitas GD
Int J Mol Sci; 2012 Sep; 13(10):12315-35. PubMed ID: 23202900
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
Szuba A; Podgórski M
Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
Vallance P; Leiper J
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
[TBL] [Abstract][Full Text] [Related]
7. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
8. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
9. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?
Caplin B; Leiper J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1343-53. PubMed ID: 22460557
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
11. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
Böger RH; Ron ES
Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
[TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Böger RH
Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
[TBL] [Abstract][Full Text] [Related]
13. Low plasma levels of L-arginine, impaired intraplatelet nitric oxide and platelet hyperaggregability: implications for cardiovascular disease in depressive patients.
Pinto VL; de Souza PF; Brunini TM; Oliveira MB; Moss MB; Siqueira MA; Ferraz MR; Mendes-Ribeiro AC
J Affect Disord; 2012 Oct; 140(2):187-92. PubMed ID: 22424639
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
Böger RH
J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
[TBL] [Abstract][Full Text] [Related]
15. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.
Achan V; Tran CT; Arrigoni F; Whitley GS; Leiper JM; Vallance P
Circ Res; 2002 Apr; 90(7):764-9. PubMed ID: 11964368
[TBL] [Abstract][Full Text] [Related]
16. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
17. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Palm F; Onozato ML; Luo Z; Wilcox CS
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
20. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
Blackwell S
Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
